SCHEMBL2280010

SCHEMBL2280010

C#CCOc1cc(C)n(C)c(=O)c1C(=O)C=Cc1cccc(OCC(=O)OC)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYSLTR2 Q9NS75 2/20 0.41
CYSLTR1 Q9Y271 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.40
ABCG2 Q9UNQ0 3/20 0.39
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2D6 P10635 2/20 0.38
NPC1 O15118 1/20 0.38
CYP1A1 P04798 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
NFKB1 P19838 1/20 0.38
RAB9A P51151 1/20 0.38
NFKB2 Q00653 1/20 0.38
RELA Q04206 1/20 0.38
CYP1B1 Q16678 1/20 0.38
ALDH1A1 P00352 2/20 0.37
PDE4B Q07343 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2280006 1.00 CYSLTR2 (0.41) CYSLTR2CYSLTR1L3MBTL1ABCG2LMNA
SCHEMBL2283102 0.92 CYSLTR2 (0.46) CYSLTR2CYSLTR1L3MBTL1ABCG2LMNA
SCHEMBL2283107 0.92 CYSLTR2 (0.46) CYSLTR2CYSLTR1L3MBTL1ABCG2LMNA
SCHEMBL2283697 0.91 ALDH1A1 (0.47) CYSLTR2CYSLTR1L3MBTL1ABCG2LMNA
SCHEMBL2283693 0.91 ALDH1A1 (0.47) CYSLTR2CYSLTR1L3MBTL1ABCG2LMNA
SCHEMBL2277984 0.89 ABCG2 (0.49) CYSLTR2CYSLTR1L3MBTL1ABCG2LMNA
SCHEMBL2277980 0.89 ABCG2 (0.49) CYSLTR2CYSLTR1L3MBTL1ABCG2LMNA
SCHEMBL2274827 0.87 CYSLTR2 (0.42) CYSLTR2CYSLTR1L3MBTL1ABCG2LMNA
SCHEMBL2274821 0.87 CYSLTR2 (0.42) CYSLTR2CYSLTR1L3MBTL1ABCG2LMNA
SCHEMBL2279976 0.86 CYSLTR2 (0.41) CYSLTR2CYSLTR1L3MBTL1ABCG2LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7989478-B2 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-08-02 US disclosed
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-09-21 US disclosed
EP-1671948-A1 CINNAMOYL COMPOUND AND USE OF THE SAME Sumitomo Chemical Company, Limited (JP) 2006-06-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211680-A1 decreases expression of a Type I collage gene in a tissue to induce a reduction in accumulation of collagen and thereby improves tissue fibrosis COL2A1, COL1A1, COL14A1 CYSLTR2 829/4885CYSLTR1 466/4885L3MBTL1 1837/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.